Compare Aurora Cannabis Inc (ACB) vs Chart Industries Inc (GTLS) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

GTLS trades at $208.73 with minimal daily movement, showing technical bullish signals from moving averages while oscillators remain neutral. The company reported $4.26B revenue for 2025 but has missed earnings expectations for three consecutive quarters, with negative profit margins and elevated valuation ratios. Recent news highlights Baker Hughes' pending $13.6B acquisition and new supply agreements supporting future growth.

Investment outlook remains mixed with strong analyst buy consensus (54%) offset by recent earnings underperformance. Key opportunities include acquisition premium potential and operational scale, while risks center on profitability challenges and integration execution. The stock's valuation appears stretched given current negative returns on equity and assets.